Skip to content

Investigating the comparative effect of high-dose intravenous sulbactam ampicillin with and without amikacin nebulizer in the treatment of patients with ventilator-associated pneumonia caused by resistant Acinetobacter bacteria.

Investigating the comparative effect of high-dose intravenous sulbactam ampicillin with and without amikacin nebulizer in the treatment of patients with ventilator-associated pneumonia caused by resistant Acinetobacter bacteria.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240529061949N1
Enrollment
72
Registered
2024-06-09
Start date
2024-06-30
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator-dependent pneumonia due to resistant Acinetobacter.

Interventions

Intervention 1: Intervention group 1: The patients of this group receive intravenous ampicillin sulbactam at a dose of 9 grams every 8 hours for 10-14 days, each dose is infused over 4 hours along wit

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients over 18 years old with ventilator-dependent pneumonia due to resistant Acinetobacter

Exclusion criteria

Exclusion criteria: Immunocompromised patients and extubated patients

Design outcomes

Primary

MeasureTime frame
Determining the effectiveness of treatment in improving the clinical condition. Timepoint: 3, 5, and 7 days after starting the treatment. Method of measurement: Improving respiratory condition and reducing lung secretions and extubation and stopping fever.;Determining the effectiveness of treatment in improving laboratory conditions. Timepoint: 3, 5 and 7 days after the start of treatment. Method of measurement: Check complete blood tests and inflammatory factors.

Secondary

MeasureTime frame
Length of hospitalization in the intensive care unit and hospital. Timepoint: Length of hospitalization. Method of measurement: Check list.;Mortality rate. Timepoint: End of study. Method of measurement: Check list.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Honarjou

Mashhad University of Medical Sciences

elhonarjou@gmail.com+98 51 3274 2006

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026